13
Egan J.M., Meneilly G.S., Elahi D. Effects of 1–mo bolus
subcutaneous administration exentid–4 in type 2 diabetes
// Am J Physiol Endocrinol Metab. - 2003. – V. 284. – P.
1072–1079.
14
Drucker DJ. Enhancing incretin action for the treatment of
type 2 diabetes // Diabetes Care. – 2003. – V.26. – P. 2929–
2940.
15
Heine R.J., Van Gaal L.F., Johns D. et al. Exenatide versus
insulin glargine in patients with suboptimalli controlled
type 2 diabetes // Ann Intern Med. – 2005. - V. 143(8). –
P. 559–569.
16
Ghosh RK, Ghosh SM, Chawla S, Jasdanwala SA. SGLT
inhibitors: a new emerging therapeutic class in the
treatment of type 2 diabetes mellitus// J Clin Pharmacol. –
2011. - [Epub ahead of print]
17
Ferranni E. Learning from glucosuria // Diabetes. – 2011.
– V. 60. – P. 695-696.
18
Isaji M. Sodium –glucose cotransporter inhibitors for
diabetes // Curr Opin Investig Drugs. – 2007. – V. 8. – P.
285-292.
19
Wright A. et al. Sulfonilurea inadequacy: ef icacy of
addition of insulin over 6 years in patients with type 2
diabetes mellitus in UK prospective Diabetes Study
(UKPDS 57) // Diabetes Care. – 2002. – V. 25. – P. 330–336.
20
UK Prospective Diabetes Study Group: UK Prospective
Diabetes Study 16: overview of 6 years therapy of type II
diabetes:
a progressive disease // Diabetes. - 1995. – V. 44. – P.
1249–1258.
Достарыңызбен бөлісу: